While the cardiovascular outcomes of SCD1 inhibition have not been addressed in humans, loss of SCD1 in Ldlr−/− mice (354) or its inhibition in Ldlr−/− / Apob 100/100 mice via ASO (355) enhanced atherosclerosis while reducing hepatic steatosis. Here, APOB is linked to fatty liver disease.